NADAC acquisition cost data for ALFUZOSIN HCL ER 10 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 47335095681 | $0.1278 | 2022-03-23 | Rx |
| 47335095681 | $0.1278 | 2022-03-23 | Rx |
| 47335095681 | $0.1278 | 2022-03-23 | Rx |
| 47335095681 | $0.1278 | 2022-03-23 | Rx |
| 13668002101 | $0.1159 | 2022-12-21 | Rx |
| 13668002105 | $0.1159 | 2022-12-21 | Rx |
| 29300015501 | $0.1159 | 2022-12-21 | Rx |
| 29300015519 | $0.1159 | 2022-12-21 | Rx |
| 47335095618 | $0.1159 | 2022-12-21 | Rx |
| 47335095688 | $0.1159 | 2022-12-21 | Rx |
Generic: Alfuzosin HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.5M | 637,890 | 185,815 | $0.4221 |
| 2020 | $23.5M | 760,988 | 200,953 | $0.4510 |
| 2021 | $25.1M | 817,998 | 226,592 | $0.4373 |
| 2022 | $26.1M | 884,009 | 246,627 | $0.4125 |
| 2023 | $27.9M | 964,261 | 271,716 | $0.4031 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.